Jesy Nelson’s Twins Diagnosed with spinal Muscular Atrophy Type 1

Former Little Mix singer Jesy Nelson has revealed her twin babies,Ocean Jade and Story Monroe Nelson-Foster,are unlikely to ever be able to walk after being diagnosed with a rare genetic condition. The news was shared via an emotional Instagram post on January 4, 2024.

Understanding Spinal Muscular Atrophy (SMA)

The 34-year-old singer, who gave birth to her twins prematurely in May with fiancé Zion Foster, has revealed they have been diagnosed with SMA1 (spinal muscular atrophy). SMA is a genetic disease affecting the motor neurons – nerve cells in the spinal cord – that control essential muscle movements like breathing, swallowing, and walking. It’s caused by a deficiency in the protein survival motor neuron (SMN). Without enough SMN protein, motor neurons die, leading to muscle weakness and atrophy (muscle wasting).

What is SMA Type 1?

SMA is classified into different types based on the age of onset and severity of symptoms. The National Institute of Neurological Disorders and Stroke (NINDS) provides comprehensive information on the different types of SMA. SMA Type 1,the most severe form,typically manifests in infancy.Key characteristics include:

• Severe muscle weakness and floppiness (hypotonia)
• Difficulty breathing and swallowing
• Inability to sit independently or hold their head up
• progressive muscle atrophy

Historically, SMA Type 1 had a very poor prognosis, with most infants not surviving beyond two years of age. However,recent advancements in treatment have significantly improved outcomes.

Treatment Options and Hope for the future

Jesy Nelson shared in her post that her twins are receiving a groundbreaking treatment called Zolgensma.Zolgensma (onasemnogene abeparvovec-xioi), developed by Novartis, is a gene therapy designed to deliver a functional copy of the SMN1 gene to the body.this aims to halt the progression of the disease and potentially restore some muscle function.

While Zolgensma is not a cure, it represents a important breakthrough in the treatment of SMA. It’s most effective when administered early in life,before significant motor neuron loss has occurred. Other treatment options include Spinraza (nusinersen), an antisense oligonucleotide that modifies the splicing of the SMN2 gene to produce more functional SMN protein, and Evrysdi (risdiplam), an oral medication that also increases SMN protein levels.

The Importance of early Diagnosis

Early diagnosis of SMA is crucial for maximizing the benefits of available treatments. Newborn screening for SMA is becoming increasingly common, allowing for prompt intervention and improved outcomes. Cure SMA is a leading organization advocating for universal newborn screening for SMA.

Key Takeaways

• Jesy Nelson’s twins have been diagnosed with SMA Type 1, a severe genetic condition affecting muscle movement.
• SMA is caused by a deficiency in the SMN protein, leading to motor neuron loss.
• Zolgensma, a gene therapy, offers a promising treatment option for SMA, particularly when administered early.
• Early diagnosis and treatment are critical for improving outcomes for individuals with SMA.

The diagnosis is undoubtedly challenging for Jesy Nelson and her family, but the availability of innovative treatments like Zolgensma offers a beacon of hope.Continued research and advocacy are essential to further improve the lives of those affected by SMA.